echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Clinical application of hydroxychloroquine in rheumatology

    Clinical application of hydroxychloroquine in rheumatology

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In patients with systemic lupus erythematosus (SLE), a higher frequency of atherosclerotic lesions is associated with poor prognos.


    Hydroxychloroquine (HCQ) has been reported to improve lifespan and dyslipidemia outcomes in SLE patients, but the mechanism is unclear

    Methods: The study included SLE patients who received supplemental HCQ between January 2016 and September 2020 and maintained low disease activi.


    method:

    Serum adipokine levels before and after hydroxychloroquine treatment :

    Serum adipokine levels before and after hydroxychloroquine treatment :

    RESULTS: Forty-one patients (4 males and 37 females, mean age 43 ± 12 years) were includ.


    result:

    Changes of serum inflammatory factors and adipokines before and after hydroxychloroquine treatment:

    Changes of serum inflammatory factors and adipokines before and after hydroxychloroquine treatment:

    Therefore, HCQ supplementation in SLE patients can improve adipokines leve.


    Supplemental HCQ therapy improves adipokines in SLE patien.


    There is a study of the relationship between hydroxychloroquine (HCQ) use and the risk of developing heart failure (HF) in rheumatoid arthritis (RA)

    Methods: In a nested case-control study, cases were residents of Olmsted County, Minnesota, who developed RA (based on 1987 American College of Rheumatology criteria) from 1980 to 2013 and developed HF after RA ons.


    method:

    Use HCQ prior to index date/HF diagnosis in RA patients according to HF status :

    Use HCQ prior to index date/HF diagnosis in RA patients according to HF status :

    Results: The study identified 143 RA cases diagnosed with HF (mean age 68 years, 62% women) and 143 non-HF RA controls (mean age 65 years, 62% wome.


    result:

    Therefore, in the study, the use of HCQ was not associated with the development of HF in RA patients


    In study, HCQ use was not associated with HF in RA patients

     

    references:

    references:

    Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi.


    Wakiya R, Ueeda K, Shimada H, Nakashima S, Kameda T, Miyatake N, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi.


    Sorour AA, Kurmann RD, Shahin YE, Crowson CS, Achenbach SJ, Mankad R, Myasoedova.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.